Figure 3.
Figure 3. Overview of treatment of TTP patients. MAHA indicates microangiopathic hemolytic anemia; PEX, plasma exchange; TMA, thrombotic microangiopathy; FBC, full blood count; plts, platelets; LDH, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; Fbg, fibrinogen; U+E, urea and electrolytes test; HCG, human chorionic gonadotropin; D+HUS, diarrhea-associated hemolytic uremic syndrome; CT, computerized tomography; MRI, magnetic resonance imaging; ECG, electrocardiogram; sd FFP, single-donor fresh-frozen plasma; pv, plasma volume; PPI, proton pump inhibitor; and HAART, highly active antiretroviral therapy.

Overview of treatment of TTP patients. MAHA indicates microangiopathic hemolytic anemia; PEX, plasma exchange; TMA, thrombotic microangiopathy; FBC, full blood count; plts, platelets; LDH, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; Fbg, fibrinogen; U+E, urea and electrolytes test; HCG, human chorionic gonadotropin; D+HUS, diarrhea-associated hemolytic uremic syndrome; CT, computerized tomography; MRI, magnetic resonance imaging; ECG, electrocardiogram; sd FFP, single-donor fresh-frozen plasma; pv, plasma volume; PPI, proton pump inhibitor; and HAART, highly active antiretroviral therapy.

Close Modal

or Create an Account

Close Modal
Close Modal